Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ 89 Zr]Zr-DFO-girentuximab-PET/CT and [ 18 F]FDG-PET/CT in detecting ccRCC lesions i...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2019-08, Vol.46 (9), p.1931-1939 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1939 |
|---|---|
| container_issue | 9 |
| container_start_page | 1931 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 46 |
| creator | Verhoeff, Sarah R. van Es, Suzanne C. Boon, Eline van Helden, Erik Angus, Lindsay Elias, Sjoerd G. Oosting, Sjoukje F. Aarntzen, Erik H. Brouwers, Adrienne H. Kwee, Thomas C. Heskamp, Sandra Hoekstra, Otto S. Verheul, Henk van der Veldt, Astrid A. M. de Vries, Elisabeth G. E. Boerman, Otto C. van der Graaf, Winette T. A. Oyen, Wim J. G. van Herpen, Carla M. L. |
| description | Purpose
The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.
Methods
Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [
89
Zr]Zr-DFO-girentuximab or [
18
F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV
max
) were measured.
Results
A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [
89
Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62
, p
= 0.001), respectively, and more than CT and [
18
F]FDG-PET/CT combined (84% (95%CI:79–88,
p
|
| doi_str_mv | 10.1007/s00259-019-04358-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6647180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2257717999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-b98b73c8a2d4ffb8c8546e1a638628a16427ac0c9b85710061b8afb9e68557fc3</originalsourceid><addsrcrecordid>eNp9kc1vFCEYxonR2Fr9BzwYEi9exgIzfF1MzLZbTTaph_XSpiHAMFuaGWYFxrpX_3IZt64fBw_AS_jx8D48ALzE6C1GiJ8mhAiVFcJlNDUVlXwEjjErW46EfHyoOToCz1K6QwgLIuRTcFRjzAnB5Bh8X7nkxwBbl53Nc2V28FrIq3hzFauz5WW18dGFPH3zgzZQhxZeY7G8WZ5dVJ_O16eLNfQBbnX2BUrw3udbGNx9v4Ot15swJtfCwWWdckEsLFK6h9b1ZdLR-jAO-jl40uk-uRcP6wn4vDxfLz5Uq8uLj4v3q8o2vMmVkcLw2gpN2qbrjLCCNsxhzWrBiNCYNYRri6w0gvLyPwwboTsjHROU8s7WJ-DdXnc7mcG1tjQcda-2sTiLOzVqr_4-Cf5WbcavirGGY4GKwJsHgTh-mVzKavBp9qKDG6ekCKGcYy6lLOjrf9C7cYrF-0zVVHKKGl4osqdsHFOKrjs0g5GaI1b7iFWJWP2MWM3Sr_60cbjyK9MC1HsglaOwcfH32_-R_QGFJLIx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2235975047</pqid></control><display><type>article</type><title>Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma</title><source>Springer Nature - Complete Springer Journals</source><creator>Verhoeff, Sarah R. ; van Es, Suzanne C. ; Boon, Eline ; van Helden, Erik ; Angus, Lindsay ; Elias, Sjoerd G. ; Oosting, Sjoukje F. ; Aarntzen, Erik H. ; Brouwers, Adrienne H. ; Kwee, Thomas C. ; Heskamp, Sandra ; Hoekstra, Otto S. ; Verheul, Henk ; van der Veldt, Astrid A. M. ; de Vries, Elisabeth G. E. ; Boerman, Otto C. ; van der Graaf, Winette T. A. ; Oyen, Wim J. G. ; van Herpen, Carla M. L.</creator><creatorcontrib>Verhoeff, Sarah R. ; van Es, Suzanne C. ; Boon, Eline ; van Helden, Erik ; Angus, Lindsay ; Elias, Sjoerd G. ; Oosting, Sjoukje F. ; Aarntzen, Erik H. ; Brouwers, Adrienne H. ; Kwee, Thomas C. ; Heskamp, Sandra ; Hoekstra, Otto S. ; Verheul, Henk ; van der Veldt, Astrid A. M. ; de Vries, Elisabeth G. E. ; Boerman, Otto C. ; van der Graaf, Winette T. A. ; Oyen, Wim J. G. ; van Herpen, Carla M. L.</creatorcontrib><description>Purpose
The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.
Methods
Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [
89
Zr]Zr-DFO-girentuximab or [
18
F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV
max
) were measured.
Results
A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [
89
Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62
, p
= 0.001), respectively, and more than CT and [
18
F]FDG-PET/CT combined (84% (95%CI:79–88,
p
< 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.
Conclusions
The addition of [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-019-04358-9</identifier><identifier>PMID: 31172212</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer ; Cardiology ; Clear cell-type renal cell carcinoma ; Computed tomography ; Consortia ; Fluorine isotopes ; Imaging ; Kidney cancer ; Lesions ; Lungs ; Lymph nodes ; Lymphatic system ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Nodes ; Nuclear Medicine ; Oncology ; Oncology – Genitourinary ; Original ; Original Article ; Orthopedics ; Positron emission ; Positron emission tomography ; Prognosis ; Radiology ; Soft tissues ; Tomography ; Zirconium isotopes</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2019-08, Vol.46 (9), p.1931-1939</ispartof><rights>The Author(s) 2019</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-b98b73c8a2d4ffb8c8546e1a638628a16427ac0c9b85710061b8afb9e68557fc3</citedby><cites>FETCH-LOGICAL-c474t-b98b73c8a2d4ffb8c8546e1a638628a16427ac0c9b85710061b8afb9e68557fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-019-04358-9$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-019-04358-9$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31172212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verhoeff, Sarah R.</creatorcontrib><creatorcontrib>van Es, Suzanne C.</creatorcontrib><creatorcontrib>Boon, Eline</creatorcontrib><creatorcontrib>van Helden, Erik</creatorcontrib><creatorcontrib>Angus, Lindsay</creatorcontrib><creatorcontrib>Elias, Sjoerd G.</creatorcontrib><creatorcontrib>Oosting, Sjoukje F.</creatorcontrib><creatorcontrib>Aarntzen, Erik H.</creatorcontrib><creatorcontrib>Brouwers, Adrienne H.</creatorcontrib><creatorcontrib>Kwee, Thomas C.</creatorcontrib><creatorcontrib>Heskamp, Sandra</creatorcontrib><creatorcontrib>Hoekstra, Otto S.</creatorcontrib><creatorcontrib>Verheul, Henk</creatorcontrib><creatorcontrib>van der Veldt, Astrid A. M.</creatorcontrib><creatorcontrib>de Vries, Elisabeth G. E.</creatorcontrib><creatorcontrib>Boerman, Otto C.</creatorcontrib><creatorcontrib>van der Graaf, Winette T. A.</creatorcontrib><creatorcontrib>Oyen, Wim J. G.</creatorcontrib><creatorcontrib>van Herpen, Carla M. L.</creatorcontrib><title>Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.
Methods
Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [
89
Zr]Zr-DFO-girentuximab or [
18
F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV
max
) were measured.
Results
A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [
89
Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62
, p
= 0.001), respectively, and more than CT and [
18
F]FDG-PET/CT combined (84% (95%CI:79–88,
p
< 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.
Conclusions
The addition of [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.</description><subject>Cancer</subject><subject>Cardiology</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Computed tomography</subject><subject>Consortia</subject><subject>Fluorine isotopes</subject><subject>Imaging</subject><subject>Kidney cancer</subject><subject>Lesions</subject><subject>Lungs</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Nodes</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Genitourinary</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prognosis</subject><subject>Radiology</subject><subject>Soft tissues</subject><subject>Tomography</subject><subject>Zirconium isotopes</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1vFCEYxonR2Fr9BzwYEi9exgIzfF1MzLZbTTaph_XSpiHAMFuaGWYFxrpX_3IZt64fBw_AS_jx8D48ALzE6C1GiJ8mhAiVFcJlNDUVlXwEjjErW46EfHyoOToCz1K6QwgLIuRTcFRjzAnB5Bh8X7nkxwBbl53Nc2V28FrIq3hzFauz5WW18dGFPH3zgzZQhxZeY7G8WZ5dVJ_O16eLNfQBbnX2BUrw3udbGNx9v4Ot15swJtfCwWWdckEsLFK6h9b1ZdLR-jAO-jl40uk-uRcP6wn4vDxfLz5Uq8uLj4v3q8o2vMmVkcLw2gpN2qbrjLCCNsxhzWrBiNCYNYRri6w0gvLyPwwboTsjHROU8s7WJ-DdXnc7mcG1tjQcda-2sTiLOzVqr_4-Cf5WbcavirGGY4GKwJsHgTh-mVzKavBp9qKDG6ekCKGcYy6lLOjrf9C7cYrF-0zVVHKKGl4osqdsHFOKrjs0g5GaI1b7iFWJWP2MWM3Sr_60cbjyK9MC1HsglaOwcfH32_-R_QGFJLIx</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Verhoeff, Sarah R.</creator><creator>van Es, Suzanne C.</creator><creator>Boon, Eline</creator><creator>van Helden, Erik</creator><creator>Angus, Lindsay</creator><creator>Elias, Sjoerd G.</creator><creator>Oosting, Sjoukje F.</creator><creator>Aarntzen, Erik H.</creator><creator>Brouwers, Adrienne H.</creator><creator>Kwee, Thomas C.</creator><creator>Heskamp, Sandra</creator><creator>Hoekstra, Otto S.</creator><creator>Verheul, Henk</creator><creator>van der Veldt, Astrid A. M.</creator><creator>de Vries, Elisabeth G. E.</creator><creator>Boerman, Otto C.</creator><creator>van der Graaf, Winette T. A.</creator><creator>Oyen, Wim J. G.</creator><creator>van Herpen, Carla M. L.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190801</creationdate><title>Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma</title><author>Verhoeff, Sarah R. ; van Es, Suzanne C. ; Boon, Eline ; van Helden, Erik ; Angus, Lindsay ; Elias, Sjoerd G. ; Oosting, Sjoukje F. ; Aarntzen, Erik H. ; Brouwers, Adrienne H. ; Kwee, Thomas C. ; Heskamp, Sandra ; Hoekstra, Otto S. ; Verheul, Henk ; van der Veldt, Astrid A. M. ; de Vries, Elisabeth G. E. ; Boerman, Otto C. ; van der Graaf, Winette T. A. ; Oyen, Wim J. G. ; van Herpen, Carla M. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-b98b73c8a2d4ffb8c8546e1a638628a16427ac0c9b85710061b8afb9e68557fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer</topic><topic>Cardiology</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Computed tomography</topic><topic>Consortia</topic><topic>Fluorine isotopes</topic><topic>Imaging</topic><topic>Kidney cancer</topic><topic>Lesions</topic><topic>Lungs</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Nodes</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Genitourinary</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prognosis</topic><topic>Radiology</topic><topic>Soft tissues</topic><topic>Tomography</topic><topic>Zirconium isotopes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verhoeff, Sarah R.</creatorcontrib><creatorcontrib>van Es, Suzanne C.</creatorcontrib><creatorcontrib>Boon, Eline</creatorcontrib><creatorcontrib>van Helden, Erik</creatorcontrib><creatorcontrib>Angus, Lindsay</creatorcontrib><creatorcontrib>Elias, Sjoerd G.</creatorcontrib><creatorcontrib>Oosting, Sjoukje F.</creatorcontrib><creatorcontrib>Aarntzen, Erik H.</creatorcontrib><creatorcontrib>Brouwers, Adrienne H.</creatorcontrib><creatorcontrib>Kwee, Thomas C.</creatorcontrib><creatorcontrib>Heskamp, Sandra</creatorcontrib><creatorcontrib>Hoekstra, Otto S.</creatorcontrib><creatorcontrib>Verheul, Henk</creatorcontrib><creatorcontrib>van der Veldt, Astrid A. M.</creatorcontrib><creatorcontrib>de Vries, Elisabeth G. E.</creatorcontrib><creatorcontrib>Boerman, Otto C.</creatorcontrib><creatorcontrib>van der Graaf, Winette T. A.</creatorcontrib><creatorcontrib>Oyen, Wim J. G.</creatorcontrib><creatorcontrib>van Herpen, Carla M. L.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verhoeff, Sarah R.</au><au>van Es, Suzanne C.</au><au>Boon, Eline</au><au>van Helden, Erik</au><au>Angus, Lindsay</au><au>Elias, Sjoerd G.</au><au>Oosting, Sjoukje F.</au><au>Aarntzen, Erik H.</au><au>Brouwers, Adrienne H.</au><au>Kwee, Thomas C.</au><au>Heskamp, Sandra</au><au>Hoekstra, Otto S.</au><au>Verheul, Henk</au><au>van der Veldt, Astrid A. M.</au><au>de Vries, Elisabeth G. E.</au><au>Boerman, Otto C.</au><au>van der Graaf, Winette T. A.</au><au>Oyen, Wim J. G.</au><au>van Herpen, Carla M. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>46</volume><issue>9</issue><spage>1931</spage><epage>1939</epage><pages>1931-1939</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.
Methods
Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [
89
Zr]Zr-DFO-girentuximab or [
18
F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV
max
) were measured.
Results
A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [
89
Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62
, p
= 0.001), respectively, and more than CT and [
18
F]FDG-PET/CT combined (84% (95%CI:79–88,
p
< 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.
Conclusions
The addition of [
89
Zr]Zr-DFO-girentuximab-PET/CT and [
18
F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31172212</pmid><doi>10.1007/s00259-019-04358-9</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2019-08, Vol.46 (9), p.1931-1939 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6647180 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Cancer Cardiology Clear cell-type renal cell carcinoma Computed tomography Consortia Fluorine isotopes Imaging Kidney cancer Lesions Lungs Lymph nodes Lymphatic system Medicine Medicine & Public Health Metastases Metastasis Nodes Nuclear Medicine Oncology Oncology – Genitourinary Original Original Article Orthopedics Positron emission Positron emission tomography Prognosis Radiology Soft tissues Tomography Zirconium isotopes |
| title | Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lesion%20detection%20by%20%5B89Zr%5DZr-DFO-girentuximab%20and%20%5B18F%5DFDG-PET/CT%20in%20patients%20with%20newly%20diagnosed%20metastatic%20renal%20cell%20carcinoma&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Verhoeff,%20Sarah%20R.&rft.date=2019-08-01&rft.volume=46&rft.issue=9&rft.spage=1931&rft.epage=1939&rft.pages=1931-1939&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-019-04358-9&rft_dat=%3Cproquest_pubme%3E2257717999%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2235975047&rft_id=info:pmid/31172212&rfr_iscdi=true |